Corrigendum: Melatonin Protects MCAO-Induced Neuronal Loss via NR2A Mediated Prosurvival Pathways

Frontiers in Pharmacology

Fang Liu²  Shupeng Li²  Yuhua Jiang³  Xifei Yang⁴  Gongping Liu⁵  Lina T. Al Kury⁶  Phil-Ok Koh⁷  Tao Li⁸  Muzaffar Abbas⁹  Fawad Ali Shah^1,11  Alam Zeb^1,11 

[1]0Department of Psychiatry, University of Toronto, Toronto, ON, Canada

[2]1Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Center for Disease Control and Prevention, Shenzhen, China

[3]2Cancer Centre, The Second Hospital of Shandong University, Jinan, China

[4]Centre for Addiction and Mental Health, Campbell Research Institute, Toronto, ON, Canada

[5]Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China

[6]College of Natural and Health Sciences, Zayed University, Abu Dhabi, United Arab Emirates

[7]Department of Anatomy, College of Veterinary Medicine, Research Institute of Life Science, Gyeongsang National University, Jinju, South Korea

[8]Department of Forensic Medicine, School of Medicine, Xi’an Jiaotong University, Xi’an, China

[9]Department of Pharmacy, Capital University of Science and Technology, Islamabad, Pakistan

[10]Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

[11]Riphah Institute of Pharmaceutical Sciences, Riphah International University Islamabad, Islamabad, Pakistan

[12]State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China

关键词: melatonin;    ischemic stroke;    NMDA receptor;    AMPA receptor;    PI3K/AKT/GSK3 pathway;   

DOI  :  10.3389/fphar.2019.00702

来源: DOAJ

【 授权许可】

Unknown